ArticleEClinicalMedicine2024

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Pau Abrisqueta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.